iShares US Pharmaceuticals ETF
113 hedge funds and large institutions have $118M invested in iShares US Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 19 closing their positions.
114% more call options, than puts
Call options by funds: $441K | Put options by funds: $206K
6.75% less ownership
Funds ownership: 99.65% → 92.89% (-6.8%)
10% less funds holding
Funds holding: 125 → 113 (-12)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
18% less capital invested
Capital invested by funds: $143M → $118M (-$25.2M)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.15M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.32M |
| 3 |
PGFC
Peapack-Gladstone Financial Corp
Bedminster,
New Jersey
|
+$3.15M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$2.48M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EE
EWG Elevate
Roseville,
California
|
-$6.35M |
| 2 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$5.05M |
| 3 |
Goldman Sachs
New York
|
-$3.92M |
| 4 |
AWS
Atria Wealth Solutions
New York
|
-$3.22M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.21M |
IHE Hedge Fund Activity: Q3 2022 in Review
113 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2022, worth a combined $118M — down 18% from $143M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of IHE and 8 opened new positions — a net loss of 11 holders — while 30 trimmed existing stakes and 27 added.
The largest buyer was Susquehanna International Group, adding an estimated $4.15M. The largest seller was EWG Elevate, exiting entirely with an estimated $6.35M sold.
- 113 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2022, down from 125 in Q2 2022.
- Funds reported $118M of iShares US Pharmaceuticals ETF stock for Q3 2022, down 18% quarter-over-quarter.
- 8 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2022 and 19 closed out, a net change of -11 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2022 was Susquehanna International Group, an estimated $4.15M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2022 was EWG Elevate, an estimated $6.35M sold.
Based on aggregated 13F filings for Q3 2022.